Gliclazide
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Diabetes & Endocrine treatment.
🧴 Clinical Application
Take orally once daily as a single dose with breakfast with water. Swallow tablets whole; do not break, chew, or crush. Must be taken with food.
⚠️ Side Effects
Common: Mild hypoglycemia, dyspepsia, abdominal pain, nausea, constipation. Rare/Severe: Severe hypoglycemia, allergic skin reactions, and hepatic enzyme elevation.
🛡️ Safety Warnings
Do not skip meals after taking. Contraindicated in type 1 diabetes, ketoacidosis, and severe renal or hepatic failure. Monitor blood glucose regularly.
Jan Aushadhi Products containing Gliclazide
Found 10 generic formulation(s) containing this active ingredient.
Gliclazide Tablets 40 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide Tablets 80 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide Extended release Tablets 60 mg
Gliclazide (Modified Release 30 mg, 60 mg) is a second-generation oral sulfonylurea with selective pancreatic tropism on the WHO Model List of Essential Medicines. It selectively binds to SUR1 receptors with fast reversible kinetics, restoring early first-phase insulin secretion and protecting vascular endothelium against oxidative stress via free radical-scavenging properties. Modified-release tablets provide steady 24-hour glycemic coverage with low hypoglycemia and weight gain risk. Indicated for type 2 diabetes mellitus in adults.
Gliclazide 80mg + Metformin Hydrochloride 500mg Tablets
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Gliclazide 60mg (Modified Release) + Metformin 500mg (Extended Release) Tablets
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Gliclazide 60 mg (Extended Release) + Metformin Hydrochloride 1000 mg (Extended Release) Tablets
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Gliclazide + Pioglitazone + Metformin Tablet (30/15/500 Mg)
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Gliclazide + Pioglitazone + Metformin Tablet (60/15/500 Mg)
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Voglibose + Metformin + Gliclazide Tablet (0.2/500/80 Mg)
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Voglibose + Metformin + Gliclazide Tablet (0.3/500/80 Mg)
Metformin Hydrochloride and Gliclazide (Modified Release) combines an insulin sensitizer with a selectively reversible sulfonylurea. Gliclazide selectively binds to pancreatic beta-cell SUR1 receptors with fast on-off association kinetics, restoring the physiological first-phase insulin secretory burst and offering lower hypoglycemia risk than glibenclamide, while metformin reduces hepatic glucose output. Indicated for type 2 diabetes mellitus when monotherapy provides insufficient glycemic control.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Gliclazide.
Frequently Asked Questions (FAQ)
Get answers to common queries about Gliclazide generics.